Sanofi manufactures Admelog [1].
Who Else Makes Insulin Lispro Products?
While Sanofi is the manufacturer of Admelog, other companies also produce insulin lispro products. These include Eli Lilly and Company, which makes Humalog, the reference biologic for Admelog [2]. Additionally, biosimilar versions of insulin lispro are available from manufacturers like Samsung Bioepis, which offers its product under the brand name Insulin Lispro (Samsung Bioepis) [3].
What is the Difference Between Admelog and Humalog?
Admelog is a brand name for insulin lispro produced by Sanofi [1]. Humalog is another brand name for insulin lispro, manufactured by Eli Lilly and Company [2]. Admelog is considered a follow-on product to Humalog [4]. While both are insulin lispro, regulatory approvals and specific manufacturing processes can lead to subtle differences, though they are generally considered interchangeable for therapeutic purposes [3, 4].
When Does Admelog's Patent Expire?
Details regarding specific patent expiry dates for Admelog are typically tracked by specialized patent intelligence services [5]. Patent expiry is a critical factor for the introduction of generic or biosimilar competition. Information on the patent landscape for specific drugs like Admelog can be found on resources such as DrugPatentWatch.com [5].
How is Admelog Regulated?
Admelog, as a biosimilar to Humalog, undergoes rigorous regulatory review by agencies like the U.S. Food and Drug Administration (FDA). The FDA evaluates biosimilarity based on analytical studies, animal studies, and clinical studies to demonstrate that the biosimilar is highly similar to the reference product, with no clinically meaningful differences in safety, purity, and potency [3].